Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 61

    1.

    High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.

    Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, Matsumura N, Udagawa Y, Saito T, Itamochi H, Takano M, Miyagi E, Sudo T, Ushijima K, Iwase H, Seki H, Terao Y, Enomoto T, Mikami M, Akazawa K, Tsuda H, Moriya T, Tajima A, Inoue I, Tanaka K; Japanese Serous Ovarian Cancer Study Group.

    Clin Cancer Res. 2012 Mar 1;18(5):1374-85. Epub 2012 Jan 12.

    PMID:
    22241791
    [PubMed - in process]
    2.

    IL-6 and ovarian cancer--letter.

    Locasale JW, Zeskind B.

    Clin Cancer Res. 2011 Dec 15;17(24):7837; author reply 7838. Epub 2011 Dec 6. No abstract available.

    PMID:
    22147939
    [PubMed - in process]
    3.

    Error occurred: cannot get document summary

    PMID:
    22147938

    4.

    Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

    Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN.

    Clin Cancer Res. 2012 Feb 1;18(3):869-81. Epub 2011 Dec 5.

    PMID:
    22142828
    [PubMed - indexed for MEDLINE]
    5.

    A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.

    Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL.

    Clin Cancer Res. 2011 Nov 15;17(22):7164-73. Epub 2011 Nov 8.

    PMID:
    22068656
    [PubMed - indexed for MEDLINE]
    6.

    hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.

    Wittinger M, Vanhara P, El-Gazzar A, Savarese-Brenner B, Pils D, Anees M, Grunt TW, Sibilia M, Holcmann M, Horvat R, Schemper M, Zeillinger R, Schöfer C, Dolznig H, Horak P, Krainer M.

    Clin Cancer Res. 2011 Dec 15;17(24):7816-27. Epub 2011 Oct 20.

    PMID:
    22016507
    [PubMed - in process]
    7.

    Error occurred: cannot get document summary

    PMID:
    22003075

    8.

    KRAS rs61764370 in Epithelial Ovarian Cancer-Letter.

    Weidhaas JB, Slack FJ.

    Clin Cancer Res. 2011 Oct 15;17(20):6600; author reply 6601. No abstract available.

    PMID:
    22003074
    [PubMed - indexed for MEDLINE]
    9.

    iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.

    Jiang L, Siu MK, Wong OG, Tam KF, Lu X, Lam EW, Ngan HY, Le XF, Wong ES, Monteiro LJ, Chan HY, Cheung AN.

    Clin Cancer Res. 2011 Nov 1;17(21):6924-33. Epub 2011 Sep 16.

    PMID:
    21926165
    [PubMed - indexed for MEDLINE]
    10.

    A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.

    Miyamoto S, Iwamoto R, Furuya A, Takahashi K, Sasaki Y, Ando H, Yotsumoto F, Yoneda T, Hamaoka M, Yagi H, Murakami T, Hori S, Shitara K, Mekada E.

    Clin Cancer Res. 2011 Nov 1;17(21):6733-41. Epub 2011 Sep 14.

    PMID:
    21918176
    [PubMed - indexed for MEDLINE]
    11.

    BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival.

    Marchion DC, Cottrill HM, Xiong Y, Chen N, Bicaku E, Fulp WJ, Bansal N, Chon HS, Stickles XB, Kamath SG, Hakam A, Li L, Su D, Moreno C, Judson PL, Berchuck A, Wenham RM, Apte SM, Gonzalez-Bosquet J, Bloom GC, Eschrich SA, Sebti S, Chen DT, Lancaster JM.

    Clin Cancer Res. 2011 Oct 1;17(19):6356-66. Epub 2011 Aug 17.

    PMID:
    21849418
    [PubMed - indexed for MEDLINE]
    12.

    Interleukin-6 as a therapeutic target in human ovarian cancer.

    Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR.

    Clin Cancer Res. 2011 Sep 15;17(18):6083-96. Epub 2011 Jul 27.

    PMID:
    21795409
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    13.

    Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.

    Steg AD, Katre AA, Goodman B, Han HD, Nick AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK, Landen CN.

    Clin Cancer Res. 2011 Sep 1;17(17):5674-85. Epub 2011 Jul 13.

    PMID:
    21753153
    [PubMed - indexed for MEDLINE]
    14.

    Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients.

    Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, Duan S, Zhang W, Kistner EO, Chen P, Beesley J, Mi S, O'Donnell PH, Fraiman YS, Das S, Cox NJ, Lu Y, Macgregor S, Goode EL, Vierkant RA, Fridley BL, Hogdall E, Kjaer SK, Jensen A, Moysich KB, Grasela M, Odunsi K, Brown R, Paul J, Lambrechts D, Despierre E, Vergote I, Gross J, Karlan BY, Defazio A, Chenevix-Trench G; Australian Ovarian Cancer Study Group, Dolan ME.

    Clin Cancer Res. 2011 Aug 15;17(16):5490-500. doi: 10.1158/1078-0432.CCR-11-0724. Epub 2011 Jun 24.

    PMID:
    21705454
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    15.

    The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.

    Mabuchi S, Hisamatsu T, Kawase C, Hayashi M, Sawada K, Mimura K, Takahashi K, Takahashi T, Kurachi H, Kimura T.

    Clin Cancer Res. 2011 Jul 1;17(13):4462-73. Epub 2011 May 27.

    PMID:
    21622721
    [PubMed - indexed for MEDLINE]
    16.

    Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.

    Itamochi H, Oishi T, Shimada M, Sato S, Uegaki K, Naniwa J, Sato S, Nonaka M, Terakawa N, Kigawa J, Harada T.

    Clin Cancer Res. 2011 Jul 15;17(14):4742-50. Epub 2011 May 24.

    PMID:
    21610153
    [PubMed - indexed for MEDLINE]
    17.

    Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.

    Faratian D, Zweemer AJ, Nagumo Y, Sims AH, Muir M, Dodds M, Mullen P, Um I, Kay C, Hasmann M, Harrison DJ, Langdon SP.

    Clin Cancer Res. 2011 Jul 1;17(13):4451-61. Epub 2011 May 13.

    PMID:
    21571868
    [PubMed - indexed for MEDLINE]
    18.

    Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.

    Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel E.

    Clin Cancer Res. 2011 Jun 15;17(12):4042-51. Epub 2011 May 6.

    PMID:
    21551255
    [PubMed - indexed for MEDLINE]
    19.

    Dopamine blocks stress-mediated ovarian carcinoma growth.

    Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood AK.

    Clin Cancer Res. 2011 Jun 1;17(11):3649-59. Epub 2011 Apr 29.

    PMID:
    21531818
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.

    Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G.

    Clin Cancer Res. 2011 Jun 1;17(11):3716-26. Epub 2011 Apr 21.

    PMID:
    21512144
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk